Top

Current Treatment Options in Cardiovascular Medicine

Published in:

01-07-2016 | Cardio-oncology (M Fradley, Section Editor)

Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity

Authors: Umberto Campia, MD, MSc, FACC, Ana Barac, MD, PhD, FACC

Published in: Current Treatment Options in Cardiovascular Medicine | Issue 7/2016

Opinion statement

Several cancer treatments are associated with vascular toxicity, mainly mediated by their effects on endothelial cell function. In turn, vascular dysfunction may contribute to cardiac damage and other cardiovascular side effects such as hypertension, stroke, and arterial and venous thrombosis. Aerobic exercise is associated with numerous beneficial effects on the endothelium and on cardiovascular risk factors, and may potentially modulate some of the mechanisms of vascular damage associated with antineoplastic therapies, thereby reducing their cardiovascular toxicity. To date, only a very limited number of studies have focused on the effects of supervised exercise on endothelial function in cancer patients undergoing treatment and molecular mechanisms remain to be explored. Further mechanistic, translational, and clinical research is needed to investigate the potential protective role of exercise on the vascular toxicity of cancer treatments.

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.21332.CrossRefPubMed

Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47. doi:10.1016/j.jacc.2009.02.050.CrossRefPubMed

Mason C, Alfano CM, Smith AW, Wang CY, Neuhouser ML, Duggan C, et al. Long-term physical activity trends in breast cancer survivors. Cancer Epidemiol Biomark Prev: a publication of the American Association for Cancer Research. 2013;22(6):1153–61. doi:10.1158/1055-9965.EPI-13-0141. Cosponsored by the American Society of Preventive Oncology.CrossRef

Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 2009;114(1):121–7. doi:10.1016/j.ygyno.2009.03.039.CrossRefPubMed

Jung HS, Myung SK, Kim BS, Seo HG. Metabolic syndrome in adult cancer survivors: a meta-analysis. Diabetes Res Clin Pract. 2012;95(2):275–82. doi:10.1016/j.diabres.2011.08.029.CrossRefPubMed

Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64(9):938–45. doi:10.1016/j.jacc.2014.06.1167.CrossRefPubMed

U.S. Department of Health and Human Services. Physical activity and health: a report of the surgeon general. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. 1996. http://www.cdc.gov/nccdphp/sgr/index.htm. Accessed 15 Apr 2016.

8.•

Soares-Miranda L, Siscovick DS, Psaty BM, Longstreth Jr WT, Mozaffarian D. Physical activity and risk of coronary heart disease and stroke in older adults: The Cardiovascular Health Study. Circulation. 2015;133(2):147–55. doi:10.1161/CIRCULATIONAHA.115.018323. This study shows a strong association between physical activity and reduced incidence of cardiovascular disease in a well studied cardiovascular cohort of older individuals.CrossRefPubMed

Cornelissen VA, Fagard RH. Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. Hypertension. 2005;46(4):667–75. doi:10.1161/01.HYP.0000184225.05629.51.CrossRefPubMed

10.

Green DJ, Walsh JH, Maiorana A, Best MJ, Taylor RR, O'Driscoll JG. Exercise-induced improvement in endothelial dysfunction is not mediated by changes in CV risk factors: pooled analysis of diverse patient populations. Am J Physiol Heart Circ Physiol. 2003;285(6):H2679–87. doi:10.1152/ajpheart.00519.2003.CrossRefPubMed

11.•

Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2016;1, CD001800. doi:10.1002/14651858.CD001800.pub3. This meta-analysis demonstrates the effect of exercise-based cardiac rehabilitation on cardiovascular mortality in patients with coronary heart disease and highlights the need for future research including diverse patient populations.PubMed

12.

Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv: Res Pract. 2010;4(2):87–100. doi:10.1007/s11764-009-0110-5.CrossRef

13.•

Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(11):815–40. doi:10.1093/jnci/djs207. A meta-analysis of 27 observational studies that indicates association between higher levels of physical activity and reduced all-cause, breast cancer-specific, and colon cancer-specific mortality. It includes preliminary data on potential surrogate biomarkers and points to the need of future studies to understand mechanisms underlying the observed associations.CrossRefPubMedPubMedCentral

14.

Betof AS, Dewhirst MW, Jones LW. Effects and potential mechanisms of exercise training on cancer progression: a translational perspective. Brain Behav Immun. 2013;30(Suppl):S75–87. doi:10.1016/j.bbi.2012.05.001.CrossRefPubMed

15.

Jones LW, Dewhirst MW. Therapeutic properties of aerobic training after a cancer diagnosis: more than a one-trick pony? J Natl Cancer Inst. 2014;106(4), dju042. doi:10.1093/jnci/dju042.CrossRefPubMedPubMedCentral

16.

Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;118(1):84–95. doi:10.1161/CIRCULATIONAHA.108.776831.CrossRefPubMedPubMedCentral

17.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34. doi:10.1056/NEJMoa060655.CrossRefPubMed

18.

Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263–302.CrossRefPubMed

19.

Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant. 2005;35(4):323–34. doi:10.1038/sj.bmt.1704763.CrossRefPubMed

20.

Sorrentino MF, Kim J, Foderaro AE, Truesdell AG. 5-fluorouracil induced cardiotoxicity: review of the literature. Cardiol J. 2012;19(5):453–8.CrossRefPubMed

21.

Tesauro M, Iantorno M, Campia U. Obesity-related metabolic syndrome and vascular complications. Int J Endocrinol. 2013;2013:534056. doi:10.1155/2013/534056.CrossRefPubMed

22.

Campia U, Choucair WK, Bryant MB, Quyyumi AA, Cardillo C, Panza JA. Role of cyclooxygenase products in the regulation of vascular tone and in the endothelial vasodilator function of normal, hypertensive, and hypercholesterolemic humans. Am J Cardiol. 2002;89(3):286–90.CrossRefPubMed

23.

Ulu N, Buikema H, van Gilst WH, Navis G. Vascular dysfunction in adriamycin nephrosis: different effects of adriamycin exposure and nephrosis. Nephrol Dial Transplant: Off Pub Eur Dial Transplant Assoc Eur Ren Assoc. 2008;23(6):1854–60. doi:10.1093/ndt/gfm911.CrossRef

24.

Duquaine D, Hirsch GA, Chakrabarti A, Han Z, Kehrer C, Brook R, et al. Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase. Vasc Med. 2003;8(2):101–7.CrossRefPubMed

25.

Kalivendi SV, Kotamraju S, Zhao H, Joseph J, Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem. 2001;276(50):47266–76. doi:10.1074/jbc.M106829200.CrossRefPubMed

26.

Dengel DR, Ness KK, Glasser SP, Williamson EB, Baker KS, Gurney JG. Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2008;30(1):20–5. doi:10.1097/MPH.0b013e318159a593.CrossRefPubMed

27.

Mabeta P, Pepper MS. A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis. 2009;12(1):81–90. doi:10.1007/s10456-009-9134-8.CrossRefPubMed

28.

Galvan L, Huang CH, Prestayko AW, Stout JT, Evans JE, Crooke ST. Inhibition of bleomycin-induced DNA breakage by superoxide dismutase. Cancer Res. 1981;41(12 Pt 1):5103–6.PubMed

29.

Singh S, De Trafford JC, Baskerville PA, Martin JF. Response of digital arteries to endothelium dependent and independent vasodilators in patients with Raynaud’s phenomenon. Eur J Clin Invest. 1995;25(3):182–5.CrossRefPubMed

30.

van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(3):467–75. doi:10.1200/JCO.2005.02.7193.CrossRef

31.

Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617–24.CrossRefPubMed

32.

van Vuuren RJ, Visagie MH, Theron AE, Joubert AM. Antimitotic drugs in the treatment of cancer. Cancer Chemother Pharmacol. 2015;76(6):1101–12. doi:10.1007/s00280-015-2903-8.CrossRefPubMedPubMedCentral

33.

Stoter G, Koopman A, Vendrik CP, Struyvenberg A, Sleyfer DT, Willemse PH, et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol Off J Am Soc Clin Oncol. 1989;7(8):1099–104.

34.

Mikaelian I, Buness A, de Vera-Mudry MC, Kanwal C, Coluccio D, Rasmussen E, et al. Primary endothelial damage is the mechanism of cardiotoxicity of tubulin-binding drugs. Toxicol Sci: off j Soc Toxicol. 2010;117(1):144–51. doi:10.1093/toxsci/kfq189.CrossRef

35.

Heron MI, Rakusan K. Proliferating cell nuclear antigen (PCNA) detection of cellular proliferation in hypothyroid and hyperthyroid rat hearts. J Mol Cell Cardiol. 1995;27(7):1393–403. doi:10.1006/jmcc.1995.0132.CrossRefPubMed

36.

Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother. 1994;28(3):374–8.PubMed

37.

Cwikiel M, Eskilsson J, Albertsson M, Stavenow L. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol: off j Eur Soc Med Oncol / ESMO. 1996;7(7):731–7.CrossRef

38.

Cwikiel M, Zhang B, Eskilsson J, Wieslander JB, Albertsson M. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc. 1995;9(2):561–76.PubMed

39.

Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc. 1996;10(3):805–18. discussion 19.PubMed

40.

Luwaert RJ, Descamps O, Majois F, Chaudron JM, Beauduin M. Coronary artery spasm induced by 5-fluorouracil. Eur Heart J. 1991;12(3):468–70.PubMed

41.

Sudhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol: off j Eur Soc Med Oncol. 2004;15(4):661–4.CrossRef

42.

Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993;53(13):3028–33.PubMed

43.

Thyss A, Gaspard MH, Marsault R, Milano G, Frelin C, Schneider M. Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. Ann Oncol: off j Eur Soc Med Oncol. 1992;3(1):88.

44.

Porta C, Moroni M, Ferrari S, Nastasi G. Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. Neoplasma. 1998;45(2):81–2.PubMed

45.

Cardillo C, Kilcoyne CM, Waclawiw M, Cannon 3rd RO, Panza JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension. 1999;33(2):753–8.CrossRefPubMed

46.

Cardillo C, Kilcoyne CM, Cannon 3rd RO, Panza JA. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension. 2000;35(6):1237–41.CrossRefPubMed

47.

Cardillo C, Campia U, Kilcoyne CM, Bryant MB, Panza JA. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation. 2002;105(4):452–6.CrossRefPubMed

48.

Cardillo C, Kilcoyne CM, Cannon 3rd RO, Panza JA. Increased activity of endogenous endothelin in patients with hypercholesterolemia. J Am Coll Cardiol. 2000;36(5):1483–8.CrossRefPubMed

49.

Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002;106(14):1783–7.CrossRefPubMed

50.

Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation. 2005;112(19):2986–92. doi:10.1161/CIRCULATIONAHA.105.553883.PubMed

51.

Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol: off j Eur Soc Med Oncol. 1994;5(6):495–505.

52.

Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res: off j Am Assoc Can Res. 2009;15(8):2594–601. doi:10.1158/1078-0432.CCR-08-2710.CrossRef

53.

Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res: off j Am Assoc Can Res. 1996;2(11):1843–9.

54.

Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61(8):3369–72.PubMed

55.

Murtagh J, Lu H, Schwartz EL. Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation. Cancer Res. 2006;66(16):8192–9. doi:10.1158/0008-5472.CAN-06-0748.CrossRefPubMed

56.

Togni M, Raber L, Cocchia R, Wenaweser P, Cook S, Windecker S, et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol. 2007;120(2):212–20. doi:10.1016/j.ijcard.2006.09.021.CrossRefPubMed

57.

Shin DI, Kim PJ, Seung KB, Kim DB, Kim MJ, Chang K, et al. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. Int Heart J. 2007;48(5):553–67.CrossRefPubMed

58.

Tofthagen C, McAllister RD, Visovsky C. Peripheral neuropathy caused by Paclitaxel and docetaxel: an evaluation and comparison of symptoms. J adv pract oncol. 2013;4(4):204–15.PubMedPubMedCentral

59.

Behar A, Pujade-Lauraine E, Maurel A, Brun MD, Chauvin FF. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol. 1997;43(6):653–8.CrossRefPubMedPubMedCentral

60.

Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. Clin Cancer Res: off j Am Assoc Can Res. 1991;9(9):1704–12.

61.

Nuver J, De Haas EC, Van Zweeden M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep. 2010;23(1):247–53.PubMed

62.

Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40(5):701–6. doi:10.1016/j.ejca.2003.12.012.CrossRefPubMed

63.

Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005;103(5):994–9. doi:10.1002/cncr.20893.CrossRefPubMed

64.

Strumberg D, Brugge S, Korn MW, Koeppen S, Ranft J, Scheiber G, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol: off j Eur Soc Med Oncol/ESMO. 2002;13(2):229–36.CrossRef

65.•

Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res. 2013;113(6):754–64. doi:10.1161/CIRCRESAHA.113.300218. An overview of mechanisms of cardiovascular effects of cancer therapies with emphasis on their role on altering cardiovascular hemostasis.CrossRefPubMedPubMedCentral

66.

Paul MK, Mukhopadhyay AK. Tyrosine kinase—role and significance in Cancer. Int J Med Sci. 2004;1(2):101–15.CrossRefPubMedPubMedCentral

67.

Barac A. Yet another player in the cardio-oncology conundrum? Deciphering the role of FLT3. J Am Coll Cardiol. 2014;63(10):1020–1. doi:10.1016/j.jacc.2013.09.058.CrossRefPubMed

68.

Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–9. doi:10.1016/S0140-6736(07)61865-0.CrossRefPubMedPubMedCentral

69.

Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012;163(2):156–63. doi:10.1016/j.ahj.2011.10.018.

70.

de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. Management of antiangiogenic therapy-induced hypertension. Hypertension. 2012;60(3):607–15. doi:10.1161/HYPERTENSIONAHA.112.196774.CrossRefPubMedPubMedCentral

71.

Kappers MH, de Beer VJ, Zhou Z, Danser AH, Sleijfer S, Duncker DJ, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension. 2012;59(1):151–7. doi:10.1161/HYPERTENSIONAHA.111.182220.CrossRefPubMed

72.

Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675–81. doi:10.1161/HYPERTENSIONAHA.109.149690.CrossRefPubMed

73.

de Jesus-Gonzalez N, Robinson E, Penchev R, von Mehren M, Heinrich MC, Tap W, et al. Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am J Hypertens. 2012;25(10):1118–23. doi:10.1038/ajh.2012.97.CrossRefPubMed

74.

Thijs AM, van Herpen CM, Verweij V, Pertijs J, van den Broek PH, van der Graaf WT, et al. Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension. J Hypertens. 2015;33(10):2075–82. doi:10.1097/HJH.0000000000000662.CrossRefPubMed

75.

Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103(9):763–73. doi:10.1093/jnci/djr128.CrossRefPubMedPubMedCentral

76.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. doi:10.1056/NEJM200103153441101.CrossRefPubMed

77.

Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol: off j Am Assoc Clin Oncol. 2002;20(5):1215–21.CrossRef

78.

Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer Jr CE, Ewer MS, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol: off j Am Assoc Clin Oncol. 2012;30(31):3792–9. doi:10.1200/JCO.2011.40.0010.CrossRef

79.

Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1), e000472. doi:10.1161/JAHA.113.000472.CrossRefPubMedPubMedCentral

80.

Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010;7(10):564–75. doi:10.1038/nrcardio.2010.121.CrossRefPubMed

81.

Pentassuglia L, Sawyer DB. The role of Neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res. 2009;315(4):627–37. doi:10.1016/j.yexcr.2008.08.015.CrossRefPubMed

82.

Bersell K, Arab S, Haring B, Kuhn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell. 2009;138(2):257–70. doi:10.1016/j.cell.2009.04.060.CrossRefPubMed

83.

Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8(5):459–65. doi:10.1038/nm0502-459.CrossRefPubMed

84.

Hedhli N, Huang Q, Kalinowski A, Palmeri M, Hu X, Russell RR, et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation. 2011;123(20):2254–62. doi:10.1161/CIRCULATIONAHA.110.991125.CrossRefPubMedPubMedCentral

85.

Hedhli N, Dobrucki LW, Kalinowski A, Zhuang ZW, Wu X, Russell 3rd RR, et al. Endothelial-derived neuregulin is an important mediator of ischaemia-induced angiogenesis and arteriogenesis. Cardiovasc Res. 2012;93(3):516–24. doi:10.1093/cvr/cvr352.CrossRefPubMed

86.

Nocon M, Hiemann T, Muller-Riemenschneider F, Thalau F, Roll S, Willich SN. Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil: official journal of the European Society of Cardiol, Work Groups Epidemiol Prev Card Rehabil Exerc Physiol. 2008;15(3):239–46. doi:10.1097/HJR.0b013e3282f55e09.CrossRef

87.

Gielen S, Schuler G, Adams V. Cardiovascular effects of exercise training: molecular mechanisms. Circulation. 2010;122(12):1221–38. doi:10.1161/CIRCULATIONAHA.110.939959.CrossRefPubMed

88.

Otsuki T, Maeda S, Iemitsu M, Saito Y, Tanimura Y, Ajisaka R, et al. Vascular endothelium-derived factors and arterial stiffness in strength- and endurance-trained men. Am J Physiol Heart Circ Physiol. 2007;292(2):H786–91. doi:10.1152/ajpheart.00678.2006.CrossRefPubMed

89.

Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. 2000;342(7):454–60. doi:10.1056/NEJM200002173420702.CrossRefPubMed

90.

De Filippis E, Cusi K, Ocampo G, Berria R, Buck S, Consoli A, et al. Exercise-induced improvement in vasodilatory function accompanies increased insulin sensitivity in obesity and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006;91(12):4903–10. doi:10.1210/jc.2006-1142.CrossRefPubMed

91.

Sandri M, Adams V, Gielen S, Linke A, Lenk K, Krankel N, et al. Effects of exercise and ischemia on mobilization and functional activation of blood-derived progenitor cells in patients with ischemic syndromes: results of 3 randomized studies. Circulation. 2005;111(25):3391–9. doi:10.1161/CIRCULATIONAHA.104.527135.CrossRefPubMed

92.

Rodriguez I, Gonzalez M. Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulation. Front Pharmacol. 2014;5:209. doi:10.3389/fphar.2014.00209.PubMedPubMedCentral

93.

Mishra SI, Scherer RW, Snyder C, Geigle P, Gotay C. The effectiveness of exercise interventions for improving health-related quality of life from diagnosis through active cancer treatment. Oncol Nurs Forum. 2015;42(1):E33–53. doi:10.1188/15.ONF.E33-E53.CrossRefPubMed

94.•

Yu AF, Jones LW. Modulation of cardiovascular toxicity in Hodgkin lymphoma: potential role and mechanisms of aerobic training. Futur Cardiol. 2015;11(4):441–52. doi:10.2217/fca.15.29. An up-to-date summary of cancer-treatment related cardiovascular effects in Hodkgin’s lymphoma survivors and evidence for the role of aerobic exercise in improving cardiovascular outcomes.CrossRef

95.

Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, et al. Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prev Res. 2013;6(9):925–37. doi:10.1158/1940-6207.CAPR-12-0416.CrossRef

96.

Jarvela LS, Niinikoski H, Heinonen OJ, Lahteenmaki PM, Arola M, Kemppainen J. Endothelial function in long-term survivors of childhood acute lymphoblastic leukemia: effects of a home-based exercise program. Pediatr Blood Cancer. 2013;60(9):1546–51. doi:10.1002/pbc.24565.CrossRefPubMed

97.

Gilbert SE, Tew GA, Fairhurst C, Bourke L, Saxton JM, Winter EM, et al. Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer. Br J Cancer. 2016;114:401–8. doi:10.1038/bjc.2015.479.CrossRefPubMed

98.

Odiete O, Hill MF, Sawyer DB. Neuregulin in cardiovascular development and disease. Circ Res. 2012;111(10):1376–85. doi:10.1161/CIRCRESAHA.112.267286.CrossRefPubMedPubMedCentral

99.

Geisberg CA, Abdallah WM, da Silva M, Silverstein C, Smith HM, Abramson V, et al. Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort. J Card Fail. 2013;19(1):10–5. doi:10.1016/j.cardfail.2012.11.006.CrossRefPubMedPubMedCentral

100.

Lebrasseur NK, Cote GM, Miller TA, Fielding RA, Sawyer DB. Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. Am J Physiol Cell Physiol. 2003;284(5):C1149–55. doi:10.1152/ajpcell.00487.2002.CrossRefPubMed

Title: Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity
Authors: Umberto Campia, MD, MSc, FACC
Ana Barac, MD, PhD, FACC
Publication date: 01-07-2016
Publisher: Springer US
Published in: Current Treatment Options in Cardiovascular Medicine / Issue 7/2016
Print ISSN: 1092-8464
Electronic ISSN: 1534-3189
DOI: https://doi.org/10.1007/s11936-016-0465-7

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity

Opinion statement

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 7/2016

Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia

Interventions for Varicose Veins: Beyond Ablation

Cardiovascular Complications of Cranial and Neck Radiation

Use of Noninvasive Imaging in Cardiac Amyloidosis

Late Cardiotoxicity: Issues for Childhood Cancer Survivors

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page